Related Experiment Videos
Thalidomide for the treatment of relapsed and refractory multiple myeloma
Rita M Cool1, Jon D Herrington
1Department of Pharmacy, Scott & White Memorial Hospital and Clinic, Temple, Texas 76508, USA.
Abstract:
Thalidomide is the first drug in over 20 years to demonstrate clinically significant activity in patients with multiple myeloma. Although the survival rate has not improved with conventional chemotherapy over the last 30 years, thalidomide has produced favorable responses in patients for whom most available therapies have failed, such as those whose disease was resistant or relapsed after standard and high-dose treatments. Despite the risk of adverse effects such as sedation and constipation, thalidomide has become an alternative therapy for patients with relapsed or refractory disease. New trials with thalidomide administered alone and in combination with other agents seem to show promise in patients with multiple myeloma, as do preliminary studies with thalidomide derivatives.
Insights
Thalidomide shows significant clinical activity in multiple myeloma patients, offering a new treatment option for relapsed or refractory disease. Despite side effects, it provides hope where other therapies failed.
Area of Science:
- Oncology
- Pharmacology
Background:
- Multiple myeloma treatment has seen limited survival improvements with conventional chemotherapy over 30 years.
- Relapsed or refractory multiple myeloma poses a significant challenge, often failing standard and high-dose treatments.
Purpose of the Study:
- To evaluate the clinical activity of thalidomide in patients with multiple myeloma.
- To assess thalidomide as an alternative therapy for relapsed or refractory multiple myeloma.
Main Methods:
- Clinical trials involving thalidomide administration.
- Assessment of patient responses to thalidomide, alone and in combination therapies.
Main Results:
- Thalidomide demonstrated clinically significant activity in multiple myeloma patients.
- Favorable responses were observed in patients resistant or relapsed after prior treatments.
- Preliminary studies with thalidomide derivatives also show promise.
Conclusions:
- Thalidomide represents a significant advancement in multiple myeloma treatment.
- It offers a viable therapeutic option for patients with refractory or relapsed disease.
- Ongoing research and thalidomide derivatives hold promise for future therapies.